Market news
BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.
Immunome FDA accepts varegacestat NDA with April 2027 PDUFA, plus ROR1 ADC catalyst and $520M cash. Click here to read more about IMNM.
Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Immunome Inc (IMNM-Q) from The Globe and Mail including charting and trades.
BOTHELL, Wash., August 11, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
BOTHELL, Wash., July 20, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.
BOTHELL, Wash., July 08, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action dat
This is the newest page. Registered accounts read further back.